FT3

Global Endocrine Testing Market Analysis/Research Report 2022-2027: Tests to Measure Thyroid-Stimulating Hormone (TSH) are Expected to Influence Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Biotechnology, First Nations in Ontario, Triiodothyronine, Androgen deficiency, FT4, Thyroid disease, COVID-19, Roche, University Medical Center Groningen, Thyroid, Department, Geriatrics, ATA, American Thyroid Association, FT3, Incidence, Patient, UN, Tobacco, Growth, Risk, Laboratory, Abbott Laboratories, TT3, Growth hormone, Woman, Smoking, Groningen, CAGR, United Nations, Technology, Serum, Research, University of Groningen, Nephrology, Hypothyroidism, TSH, Menopause, University, Hyperthyroidism, Government, Disease, Endocrine system, Man, Medical device, Vaccine, Pharmaceutical industry, Agriculture

Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Key Points: 
  • Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.
  • Since endocrine testing tools are in high demand, market players are more committed to developing new products.
  • The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.
  • As a result, the rise in TSH testing is expected to boost market growth for the global endocrine testing market.

New Study Confirms That A Commonly Used Acid-Reducing Drug Does Not Interfere with the Absorption of A Novel Liquid Levothyroxine Formulation

Retrieved on: 
Monday, October 4, 2021
Drug, Tablet, Hypothyroidism, Degenerative disease, Patient, Thyroid, Fatigue, Hair loss, Glycerol, Health, Water, FDA, Depression, GJ, Omeprazole, Constipation, Annual general meeting, Population, TSH, FT4, Thyroid disease, PPI, THE, Virginia Commonwealth University, University, Program, Arch, Internal medicine, Woman, Plasma protein binding, Medicine, Stomach, Absorption, ATA, Forgetting, Weight gain, Health care, Mouth, Cramp, American Thyroid Association, FT3, University of Pisa, IBSA, Pharmaceutical industry

Omeprazole and other PPI medications are powerful acid-reducing agents that are known to affect the performance of traditional levothyroxine treatments that come in tablet form.

Key Points: 
  • Omeprazole and other PPI medications are powerful acid-reducing agents that are known to affect the performance of traditional levothyroxine treatments that come in tablet form.
  • A second group was administered Tirosint-SOL and omeprazole at staggered times Tirosint-SOL in the morning and omeprazole in the evening, 12 hours later.
  • Based on these findings, IBSA Institut Biochimique, the sponsor of the study, is planning to seek FDA approval for a change in the approved label for Tirosint-SOL.
  • 46
    4.Canaris GJ, Manowitz NR, Mayor G, Ridgeway EC, "The Colorado Thyroid Disease Prevalence Study", Arch of Internal Medicine; 2000;160: 526-534
    5.McDermott MT.